<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Neurofibromatosis type 1 (NF1): Management and prognosis</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Neurofibromatosis type 1 (NF1): Management and prognosis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Neurofibromatosis type 1 (NF1): Management and prognosis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Bruce R Korf, MD, PhD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Mina Lobbous, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Laura K Metrock, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Marc C Patterson, MD, FRACP</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Helen V Firth, DM, FRCP, FMedSci</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">April F Eichler, MD, MPH</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 11, 2024.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H196003488"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>There are several clinically and genetically distinct forms of neurofibromatosis. Neurofibromatosis type 1 (NF1), previously known as von Recklinghausen disease, is the most common type. The hallmarks of NF1 are the multiple café-au-lait macules and associated cutaneous neurofibromas. The condition is called segmental NF1 when clinical features are limited to one area of the body due to somatic mosaicism of a pathogenic <em>NF1</em> gene variant.</p><p>The management and prognosis of NF1 are reviewed here. The pathogenesis, clinical features, and diagnosis are discussed separately (see  <a class="medical medical_review" href="/z/d/html/2939.html" rel="external">"Neurofibromatosis type 1 (NF1): Pathogenesis, clinical features, and diagnosis"</a>). The schwannoma predisposition syndromes, including <em>NF2</em>-related schwannomatosis (NF2, formerly neurofibromatosis type 2), are also discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/5206.html" rel="external">"<i>NF2</i>-related schwannomatosis (formerly neurofibromatosis type 2)"</a> and  <a class="medical medical_review" href="/z/d/html/16350.html" rel="external">"Schwannomatoses related to genetic variants other than <i>NF2</i>"</a>.)</p><p class="headingAnchor" id="H196003494"><span class="h1">SURVEILLANCE FOR COMPLICATIONS</span><span class="headingEndMark"> — </span>Persons with NF1 should be cared for by a multidisciplinary team of dedicated specialists throughout their lifetime [<a href="#rid1">1</a>]. Longitudinal care for persons with NF1 aims at the early detection and symptomatic treatment of complications as they occur. The decision to obtain testing such as imaging studies depends upon the history and physical findings. Clinical evaluation appears to be more useful to detect complications than are surveillance investigations in asymptomatic patients [<a href="#rid2">2,3</a>]. Thus, for example, pediatric care guidelines do not recommend neuroimaging as a surveillance modality for optic pathway gliomas (OPGs) [<a href="#rid1">1</a>], although not all clinicians agree. (See  <a class="medical medical_review" href="/z/d/html/2939.html" rel="external">"Neurofibromatosis type 1 (NF1): Pathogenesis, clinical features, and diagnosis", section on 'Optic pathway gliomas'</a> and  <a class="medical medical_review" href="/z/d/html/2939.html" rel="external">"Neurofibromatosis type 1 (NF1): Pathogenesis, clinical features, and diagnosis", section on 'Bone abnormalities'</a>.)</p><p class="headingAnchor" id="H1141002572"><span class="h2">Annual surveillance for all children with NF1</span><span class="headingEndMark"> — </span>Consensus clinical guidelines from the American Academy of Pediatrics and the American College of Medical Genetics and Genomics are available [<a href="#rid1">1</a>]. Regular visits at yearly intervals should include:</p><p class="bulletIndent1"><span class="glyph">●</span>Physical examination:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Examine skin for new neurofibromas, signs of plexiform neurofibromas (PNs), or progression of existing lesions. (See <a class="local">'Malignant peripheral nerve sheath tumors'</a> below.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Check blood pressure for signs of hypertension [<a href="#rid4">4</a>]. (See <a class="local">'Severe hypertension'</a> below.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Evaluate growth measurements including height, weight, and head circumference. (See <a class="local">'Optic pathway gliomas'</a> below and <a class="local">'Brain tumors and hydrocephalus in patients with seizures or progressive macrocephaly'</a> below.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Evaluate for skeletal changes, including scoliosis, vertebral changes, and limb abnormalities, particularly tibial dysplasia in young patients.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A formal ophthalmologic examination, including visual screening. (See <a class="local">'Optic pathway gliomas'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Assessment for precocious puberty. Evaluate older children for early development of secondary sexual characteristics or abnormal growth acceleration that may be associated with lesions of the pituitary from optic glioma involving the chiasm. (See <a class="local">'Optic pathway gliomas'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Developmental assessment. Evaluate neurodevelopmental progress and evidence for attention-deficit disorder. (See <a class="local">'Cognitive and learning deficits'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Review of school progress. (See <a class="local">'Cognitive and learning deficits'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Monitoring of PNs. Affected persons and, for pediatric patients, their parents/caregivers should be questioned, particularly in adolescence, about any change in pain or growth pattern associated with a preexisting PN and, if found, should be evaluated for possible malignant transformation of the neurofibroma. (See  <a class="medical medical_review" href="/z/d/html/2939.html" rel="external">"Neurofibromatosis type 1 (NF1): Pathogenesis, clinical features, and diagnosis", section on 'Plexiform neurofibromas'</a> and <a class="local">'Malignant peripheral nerve sheath tumors'</a> below.)</p><p></p><p class="headingAnchor" id="H2091959914"><span class="h2">Surveillance for adults with NF1</span><span class="headingEndMark"> — </span>An expert panel of the American College of Medical Genetics and Genomics has formulated guidelines for the care of adults with NF1 [<a href="#rid5">5</a>]. Surveillance measures for the following complications were highlighted:</p><p class="bulletIndent1"><span class="glyph">●</span>Malignant peripheral nerve sheath tumor (MPNST):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>MPNST often arise from PNs. Thus, imaging is indicated for symptomatic PN (eg, progressive severe pain, rapid tumor growth, nodularity, new neurologic symptoms). Imaging of an asymptomatic PN is also reasonable if a deeper component is suspected. (See <a class="local">'Malignant peripheral nerve sheath tumors'</a> below.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The term "atypical neurofibromatous neoplasms of uncertain biologic potential" (ANNUBP) was proposed in 2016 after a consensus meeting to describe lesions that pose diagnostic challenges [<a href="#rid6">6</a>]. This diagnosis should prompt additional sampling, clinical correlation, and possibly expert pathology consultation.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Magnetic resonance imaging (MRI) is the preferred method of imaging if MPNST is suspected. 18-F fluorodeoxyglucose positron emission tomographic (FDG-PET) scanning is helpful in distinguishing MPNST from a benign PN [<a href="#rid7">7-10</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Breast cancer:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Women with NF1 are at increased risk of breast cancer and may present at an earlier age than the general population, at approximately 40 years of age, with the earliest cases reported at approximately 30 years of age. Women with NF1-related breast cancer have a significantly poorer five-year survival and excess mortality [<a href="#rid11">11</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The National Comprehensive Cancer Network guidelines recommend an annual mammogram starting at age 30 years and suggest contrast-enhanced breast MRI between ages 30 and 50 years for women with a clinical diagnosis of NF1 [<a href="#rid11">11</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Pheochromocytoma:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Adults with NF1 over 30 years of age or who are pregnant and who have hypertension or associated symptoms of palpitations, headache, or diaphoresis should have measurement of plasma-free fractionated metanephrines to assess for pheochromocytoma; this test is considered the most sensitive screening test. Persons with an equivocal screening test (less than fourfold elevation) should have a 24-hour urine collection for catecholamines and metanephrines and/or imaging screening [<a href="#rid12">12,13</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Biochemical or imaging screening for pheochromocytoma is not recommended for asymptomatic patients, although emerging literature supports screening for pheochromocytoma in persons with NF1 prior to surgical procedures, pregnancy, labor, and delivery since these procedures can trigger cardiovascular crisis [<a href="#rid12">12,13</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hypertension:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Persons with NF1 have higher risk for vasculopathy, which may manifest as renal artery stenosis with consequent hypertension, vascular occlusion, aneurysms, or arteriovenous fistulae.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Overall estimated incidence of vasculopathy in NF1 is 0.4 to 6.4 percent; the estimated incidence of cerebrovascular vasculopathy is 2 to 5 percent, with hemorrhagic strokes more predominant in both children and adults [<a href="#rid14">14</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Blood pressure should be measured at least annually in persons with NF1 since there is an increased risk of renovascular hypertension, particularly due to renal artery stenosis, in younger adults. Hypertension in adults with NF1 is usually primary (essential), but these persons should still be screened for renovascular disease, particularly if they are &lt;30 years of age, pregnant, or have abdominal bruits.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Either spiral computed tomography (CT) with contrast (CT angiography) or contrast-enhanced magnetic resonance angiography (MRA) can be used to evaluate for renal artery stenosis in patients with normal renal function. We use time-of-flight MRA (which is a noncontrast study) in those with abnormal renal function. Renal angiography is an option in persons with negative imaging but in whom renal artery stenosis is still suspected. Early detection of vasculopathies and medical and/or surgical interventions may prevent hypertension-related complications; hence, selective vascular imaging should be performed in persons with physical findings suggestive of vascular lesions.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Osteoporosis and scoliosis:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Adults should be monitored for osteoporosis.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>All persons with NF1 should be screened annually for scoliosis. Adults with scoliosis should be monitored for curve progression.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Neurocognitive and psychiatric problems:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Screening for depression is suggested for adults with NF1.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Clinicians should be alert to the possibility of attention-deficit disorder.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Cognitive impairment is common in persons with NF1, and intelligence quotient (IQ) may be reduced; however, more severe cognitive impairment should prompt the evaluation for other etiologies.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Chronic pain:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Chronic pain is common in adults with NF, but new-onset pain of increasing severity may indicate an MPNST and warrants evaluation.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Fingertip or toe pain may indicate the presence of glomus tumors.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Reproductive issues:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Preanesthesia neuraxial imaging is usually not necessary if spinal anesthesia is planned for labor and delivery.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Adults with NF1 should be counseled about risks of genetic transmission and options for prenatal or preimplantation diagnosis.</p><p></p><p class="headingAnchor" id="H3399607768"><span class="h2">Surveillance for specific complications or presentations</span></p><p class="headingAnchor" id="H196003500"><span class="h3">Optic pathway gliomas</span><span class="headingEndMark"> — </span>Because of the variable natural history of OPGs, all children with NF1 should undergo thorough ophthalmologic evaluation and regular assessments of height and pubertal development [<a href="#rid15">15-19</a>]. Ideally, ophthalmologic screening should include visual acuity testing, confrontation visual field testing, color vision testing, and assessment of pupils, eyelids, irises, fundi, and extraocular motility, although the full range of assessment may not be feasible in the infant or young child. The evaluation should begin when NF1 first is suspected and be repeated at annual intervals or when symptoms develop. In addition, patients with OPG may show evidence of central precocious puberty, diencephalic syndrome, growth hormone deficiency, or excess growth hormone [<a href="#rid19">19,20</a>].</p><p>Any child with visual symptoms or physical signs (eg, proptosis, decreased visual acuity, precocious puberty, or abnormal growth patterns) should have an MRI of the brain and orbits to investigate for an OPG. OPGs appear as an enlargement of the optic nerve or chiasm on MRI. A consensus panel convened by the Children's Tumor Foundation did not recommend neuroimaging for surveillance in asymptomatic children with NF1 [<a href="#rid17">17</a>], and many neurofibromatosis clinics follow young children with NF1 according to these guidelines [<a href="#rid21">21</a>]. Others have employed protocols that include MRI of the brain and orbits in addition to ophthalmologic examination [<a href="#rid22">22</a>].</p><p>Clinical observations suggest that systematic surveillance for OPG, particularly in the first 18 months of life, permits early intervention and may reduce complications. The outcome of systematic surveillance for OPG with MRI and ophthalmic examinations in young children with NF1 was evaluated in a clinical study of children less than six years of age [<a href="#rid23">23</a>]. OPG were detected in 9 of 69 children who were asymptomatic and had normal ophthalmic examinations (13 percent). Three of these children were treated with chemotherapy (due to progression of the lesion on subsequent MRI and/or ophthalmic examination) and retained normal visual function. A subsequent review of 826 children with NF1 who had routine MRI surveillance at one center revealed optic pathway tumors in 18 percent, with a median age of diagnosis of three years [<a href="#rid22">22</a>]. Children with no evidence of an optic pathway tumor by 18 months of age did not subsequently develop one. If this finding is confirmed, it might justify MRI screening to obviate the need for ophthalmologic follow-up in the 80 percent or more who will not have tumors. In any case, there is a consensus that it is important to make the clinical diagnosis of NF1 in very young children so that ophthalmic evaluations are initiated.</p><p>There is little consensus regarding the frequency of visual examinations and neuroimaging for children with NF1 in whom OPGs have been identified [<a href="#rid17">17</a>]. Suggested intervals have varied [<a href="#rid24">24-27</a>]. Measurement of retinal nerve fiber thickness may be helpful in sensitive detection of loss of visual acuity in children with optic gliomas [<a href="#rid28">28</a>]. The treatment of OPGs is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/5226.html" rel="external">"Optic pathway glioma", section on 'Treatment'</a>.)</p><p class="headingAnchor" id="H1741445894"><span class="h3">Brain tumors and hydrocephalus in patients with seizures or progressive macrocephaly</span><span class="headingEndMark"> — </span>An MRI of the brain should be performed when seizures are first diagnosed given the increased risk for central nervous system (CNS) tumors in NF1 [<a href="#rid29">29</a>]. A child with acute acceleration in head growth should be evaluated for hydrocephalus due to aqueductal stenosis and CNS neoplasms [<a href="#rid30">30</a>]. (See  <a class="medical medical_review" href="/z/d/html/2939.html" rel="external">"Neurofibromatosis type 1 (NF1): Pathogenesis, clinical features, and diagnosis", section on 'Other central nervous system neoplasms'</a> and  <a class="medical medical_review" href="/z/d/html/110031.html" rel="external">"Hydrocephalus in children: Clinical features and diagnosis"</a>.)</p><p class="headingAnchor" id="H196003506"><span class="h3">Malignant peripheral nerve sheath tumors</span><span class="headingEndMark"> — </span>Some experts suggest MRI screening for MPNSTs [<a href="#rid31">31</a>]. Such screening is not incorporated into NF1 guidelines, given the long period of risk (adolescence through mid-adulthood) and the variable location of tumor development. Primary care clinicians, parents/caregivers, and children entering adolescence should be educated about the risk of MPNST and strongly encouraged to report the development of any signs or symptoms suggestive of an MPNST (eg, pain, unexpected growth of a tumor, or change in texture from soft to firm) to a clinician familiar with NF1. Prompt investigation, including MRI [<a href="#rid32">32</a>] and, if concerning features are noted on imaging, FDG-PET, should be initiated in symptomatic patients. Although MRI cannot reliably distinguish benign neurofibromas from MPNSTs, use of diffusion-weighted MRI may be useful in detection of MPNST [<a href="#rid33">33</a>].</p><p>Studies have explored modalities to identify precursor lesions to MPNSTs in persons at high risk for these tumors because of <em>NF1 </em>microdeletions, ANNUBP, prior radiation therapy, and/or higher internal tumor burden of neurofibromas [<a href="#rid34">34</a>]. Those persons should undergo regular screening using MRI and/or 18F-FDG-PET SUVmax. Moreover, some experts recommend whole-body MRI at the age of 16 to 20 years to plan surveillance in adulthood and help identify high-risk groups [<a href="#rid35">35</a>]. Emerging technical advances, such as whole-body MRI combined with diffusion-weighted imaging/apparent diffusion coefficient (DWI/ADC) mapping, PET/MRI, as well as clinical and genetic data, can provide more insight into tumor characteristics [<a href="#rid6">6,36-38</a>].</p><p>Biopsy of several sites within a preexisting PN may be indicated to determine if malignant transformation has occurred.</p><p class="headingAnchor" id="H196003518"><span class="h3">Pheochromocytoma in patients with GIST</span><span class="headingEndMark"> — </span>Although pheochromocytomas are a rare finding in patients with NF1, there was a frequent co-occurrence of gastrointestinal stromal tumors (GISTs) and pheochromocytoma in one series, suggesting that any patient undergoing surgical procedures for a GIST should be first screened for the presence of a pheochromocytoma [<a href="#rid39">39</a>].</p><p class="headingAnchor" id="H3152469520"><span class="h3">Gastrointestinal symptoms</span><span class="headingEndMark"> — </span>Both children and adults may complain of symptoms of gastrointestinal discomfort, including constipation, irritable bowel syndrome, and functional dyspepsia [<a href="#rid40">40,41</a>]. There are no formal recommendations for surveillance or testing, but clinicians should be aware that children with NF1 are at increased risk for these disorders so that they can be diagnosed and treated appropriately.</p><p class="headingAnchor" id="H3940770767"><span class="h3">Muscle weakness</span><span class="headingEndMark"> — </span>Children with NF1 often display generalized muscle weakness and consequent motor developmental delay [<a href="#rid42">42,43</a>]. Muscle biopsy studies have revealed signs of lipid storage myopathy in some affected individuals [<a href="#rid44">44</a>]. A small clinical trial has shown evidence for potential benefit of L-carnitine supplementation in improving muscle strength [<a href="#rid45">45</a>], though confirmation in a larger group of children is required.</p><p class="headingAnchor" id="H3734556637"><span class="h3">Severe hypertension</span><span class="headingEndMark"> — </span>The most common causes of hypertension in NF1 are essential hypertension, pheochromocytoma, and, in adults &lt;30 years of age, renal artery stenosis. Persons with severe hypertension, particularly adults &lt;30 years of age, should be evaluated for renal artery stenosis. If that screening is negative, then patients should be evaluated for pheochromocytoma. Correction of the underlying lesion typically lowers the blood pressure in patients with renal artery stenosis or pheochromocytoma [<a href="#rid46">46</a>]. (See  <a class="medical medical_review" href="/z/d/html/6124.html" rel="external">"Ambulatory blood pressure monitoring in children"</a> and  <a class="medical medical_review" href="/z/d/html/6131.html" rel="external">"Nonemergent treatment of hypertension in children and adolescents"</a> and  <a class="medical medical_review" href="/z/d/html/6088.html" rel="external">"Evaluation of hypertension in children and adolescents"</a> and  <a class="medical medical_review" href="/z/d/html/5850.html" rel="external">"Pheochromocytoma and paraganglioma in children"</a> and <a class="local">'Surveillance for adults with NF1'</a> above.)</p><p class="headingAnchor" id="H196003530"><span class="h3">Cognitive and learning deficits</span><span class="headingEndMark"> — </span>Children with NF1 should be monitored for developmental progress. One analysis of 66 children with NF1 found that autism spectrum disorder (ASD) related symptoms were common, with one-third of the patients at risk for clinically significant ASD symptoms [<a href="#rid47">47</a>]. A careful neurologic examination should be part of the evaluation performed at yearly intervals. A developmental history should be obtained, and school progress reviewed. If areas of concern are identified, a formal educational assessment should be performed [<a href="#rid48">48</a>]. IQ testing and neuropsychologic evaluation may identify cognitive deficits early and facilitate the use of academic support in school [<a href="#rid2">2</a>]. Neuroimaging should not be part of a routine diagnostic evaluation, because of the uncertain relationship between MRI findings and learning disabilities. MRI should be performed to evaluate specific neurologic deficits, such as loss of coordination.</p><p class="headingAnchor" id="H13148423"><span class="h3">Pregnant women with NF1</span><span class="headingEndMark"> — </span>Women with NF1 are at increased risk for morbidity, particularly hypertensive and vascular complications, but not mortality during pregnancy [<a href="#rid49">49,50</a>]. Pregnant women with NF1 may benefit from management by a high-risk obstetrical service. Pregnant women with NF1 should be aware of the autosomal-dominant inheritance of the condition and the 50 percent chance that their baby will inherit the condition. Steps should be taken to ensure appropriate surveillance for the newborn infant. (See  <a class="medical medical_review" href="/z/d/html/2939.html" rel="external">"Neurofibromatosis type 1 (NF1): Pathogenesis, clinical features, and diagnosis", section on 'Epidemiology'</a> and  <a class="medical medical_review" href="/z/d/html/2939.html" rel="external">"Neurofibromatosis type 1 (NF1): Pathogenesis, clinical features, and diagnosis", section on 'Pathogenesis'</a> and  <a class="medical medical_review" href="/z/d/html/2939.html" rel="external">"Neurofibromatosis type 1 (NF1): Pathogenesis, clinical features, and diagnosis", section on 'Clinical manifestations'</a> and <a class="local">'Surveillance for adults with NF1'</a> above.)</p><p class="headingAnchor" id="H196003542"><span class="h1">TREATMENT</span><span class="headingEndMark"> — </span>There is no one overall treatment for NF1, although the use of mitogen-activated protein kinase kinase (MAPKK or MEK) inhibitors is changing the approach to management of plexiform neurofibromas (PNs) (see <a class="local">'Plexiform neurofibromas'</a> below). Clinical trials are ongoing for some clinical problems associated with the disorder [<a href="#rid51">51</a>].</p><p class="headingAnchor" id="H196003549"><span class="h2">Tumors</span><span class="headingEndMark"> — </span>The approach to treatment of the various tumors associated with NF1 depends upon the type of tumor, its effect on adjacent tissues, and related complications. Minimization of radiation treatment is a goal when planning treatment of patients with NF1 and central nervous system (CNS) tumors because of concerns about secondary CNS malignancies and vascular complications [<a href="#rid52">52-54</a>]. There is no evidence that specific NF1 mutations are associated with differential sensitivity to radiation or chemotherapy or predict response to treatment.</p><p class="headingAnchor" id="H196003555"><span class="h3">Cutaneous and subcutaneous neurofibromas</span><span class="headingEndMark"> — </span>Cutaneous and subcutaneous neurofibromas are not removed unless there is a specific need for removal (eg, pain, bleeding, interference with function, disfigurement) [<a href="#rid55">55</a>]. Various options for removal, such as surgery, laser removal, or electrodessication, are available, although long-term outcomes are not documented [<a href="#rid5">5</a>]. Some patients experience pruritus that does not usually respond to antihistamine treatment but may improve with medications used to treat neuropathic pain, such as <a class="drug drug_general" data-topicid="8483" href="/z/d/drug information/8483.html" rel="external">gabapentin</a>. (See  <a class="medical medical_review" href="/z/d/html/15269.html" rel="external">"Peripheral nerve tumors", section on 'Neurofibroma'</a>.)</p><p class="headingAnchor" id="H196003567"><span class="h3">Plexiform neurofibromas</span><span class="headingEndMark"> — </span>PNs usually involve multiple nerve fascicles, with serpiginous growth and significant vascularity. Multiple morbidities may occur, including pain, motor dysfunction, and visual loss [<a href="#rid56">56</a>], and worsening morbidity is associated with growth of the lesions [<a href="#rid57">57</a>]. PNs also can undergo malignant transformation to malignant peripheral nerve sheath tumors (MPNSTs) [<a href="#rid58">58</a>]. Surgical treatment and pain management of PNs can be a significant challenge, especially when there is progressive growth along the spinal column that results in compression of the spinal cord [<a href="#rid59">59,60</a>]. <a class="drug drug_general" data-topicid="127843" href="/z/d/drug information/127843.html" rel="external">Selumetinib</a>, an oral selective mitogen-activated protein kinase kinase (MEK) inhibitor that can induced tumor regression, was approved by the US Food and Drug Administration (FDA) in April 2020 for the treatment of pediatric patients age three years or older with symptomatic and/or progressive, inoperable NF1-related PNs [<a href="#rid61">61</a>]. (See  <a class="medical medical_review" href="/z/d/html/2939.html" rel="external">"Neurofibromatosis type 1 (NF1): Pathogenesis, clinical features, and diagnosis", section on 'Soft tissue sarcomas'</a>.)</p><p><a class="drug drug_general" data-topicid="127843" href="/z/d/drug information/127843.html" rel="external">Selumetinib</a> is used in patients with symptomatic and inoperable tumors. In a phase II multicenter trial, 50 children aged 2 to 18 years with NF1 and inoperable PNs were treated with selumetinib at a dose of 25 mg/m<sup>2</sup> by mouth twice daily [<a href="#rid62">62</a>]. A partial response, defined as a ≥20 percent decrease in tumor volume from baseline for at least four weeks, was observed in 70 percent of patients and was durable (lasting ≥1 year) in 80 percent. Mean tumor-related pain intensity scores decreased by two points after one year of treatment, and approximately 50 percent of patients experienced improvements in functional outcomes and quality of life. With longer-term follow-up in 74 children treated on phase I and II trials (median duration of treatment 57.5 monthly cycles), tumor responses were largely maintained, with 59 percent lasting 12 or more cycles [<a href="#rid63">63</a>]. Improvements in tumor pain were also sustained.</p><p>The most common clinical toxicities of MEK inhibitors are gastrointestinal, increased creatine phosphokinase (CPK), and dermatologic. Based on pooled data from over 125 treated patients, the most common adverse effects of <a class="drug drug_general" data-topicid="127843" href="/z/d/drug information/127843.html" rel="external">selumetinib</a> in patients with NF1 are diarrhea (64 percent), elevated CPK (63 percent, majority asymptomatic), acneiform rash (54 percent), mucositis (43 percent), and paronychia (41 percent) [<a href="#rid64">64</a>]. Less common but serious toxicities of selumetinib include reduced left ventricular ejection fraction and cardiomyopathy and ocular toxicity (eg, retinal detachment). No new safety signals have appeared with up to five years of treatment [<a href="#rid63">63</a>].</p><p>Clinical trials to treat PNs with other targeted therapies are ongoing. The MEK inhibitor mirdametinib was tested in a clinical trial for treatment of PN [<a href="#rid65">65</a>]. Eight of 19 participants experienced a 20 percent or greater decrease in tumor volume over the course of the study. <a class="drug drug_general" data-topicid="87299" href="/z/d/drug information/87299.html" rel="external">Cabozantinib</a>, a multiple tyrosine kinase inhibitor with targets that include cMET and vascular endothelial growth factor receptor 2 (VEGFR2), has also shown promising activity [<a href="#rid66">66</a>].</p><p>Treatment with <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">imatinib</a> or pegylated interferon has resulted in shrinkage of PNs in a limited number of patients with NF1 and PNs [<a href="#rid67">67-69</a>]. Clinical trials in patients with NF1 and PNs with the farnesyl transferase inhibitor tipifarnib [<a href="#rid49">49,70</a>], the mammalian (mechanistic) target of rapamycin (mTOR) inhibitor <a class="drug drug_general" data-topicid="10329" href="/z/d/drug information/10329.html" rel="external">sirolimus</a>, and the fibroblast inhibitor <a class="drug drug_general" data-topicid="88424" href="/z/d/drug information/88424.html" rel="external">pirfenidone</a> [<a href="#rid71">71-73</a>] have not demonstrated sufficient benefit to warrant clinical use.</p><p>Clinicians can use the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.clinicaltrials.gov%2F&amp;token=Rti1NBSWdX%2F%2FH%2FlCKGrzlGu03gYcMJXuTK3xOgZRWSzRV8srxVomMWotD038y2Xv&amp;TOPIC_ID=90123" target="_blank">ClinicalTrials.gov</a> website to inquire about open clinical trials for patients with NF1.</p><p>Surgical resection often is limited to debulking of a specific area of a large lesion, for example, when a component is impinging on the spinal cord or airway or a large soft tissue component is removed to improve cosmesis. In several series, patients were more likely to benefit from surgery when the indications were airway compression or disfigurement [<a href="#rid59">59,60</a>]. The management of chronic pain is discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/6254.html" rel="external">"Pain in children: Approach to pain assessment and overview of management principles"</a> and  <a class="medical medical_review" href="/z/d/html/126111.html" rel="external">"Approach to the management of chronic non-cancer pain in adults"</a>.)</p><p class="headingAnchor" id="H196003573"><span class="h3">Optic pathway gliomas and other low-grade gliomas</span><span class="headingEndMark"> — </span>NF1-associated low-grade gliomas (LGGs) in pediatric and adolescent patients usually behave in an indolent manner. Optimal management of LGGs is controversial. If possible, a period of observation with close monitoring of tumor size, visual function, and symptomatic progression should precede treatment initiation. When treatment is deemed necessary, first-line therapy traditionally consists of chemotherapy with <a class="drug drug_general" data-topicid="9202" href="/z/d/drug information/9202.html" rel="external">carboplatin</a> and <a class="drug drug_general" data-topicid="10045" href="/z/d/drug information/10045.html" rel="external">vincristine</a> [<a href="#rid52">52,53,74</a>]. <a class="drug drug_general" data-topicid="10044" href="/z/d/drug information/10044.html" rel="external">Vinblastine</a> monotherapy has also been shown to be effective [<a href="#rid74">74</a>].</p><p>Targeted agents are under investigation. The Pediatric Brain Tumor Consortium performed a phase II study assessing the activity of <a class="drug drug_general" data-topicid="127843" href="/z/d/drug information/127843.html" rel="external">selumetinib</a> in patients with recurrent, refractory, or progressive LGGs, including a stratum dedicated to patients with NF1-associated LGGs [<a href="#rid75">75</a>]. In this stratum, 10 of 25 patients achieved a sustained partial response. This has led to the ongoing Children's Oncology Group study (ACNS1831), which randomly assigns patients with previously untreated NF1-associated LGGs to standard-of-care <a class="drug drug_general" data-topicid="9202" href="/z/d/drug information/9202.html" rel="external">carboplatin</a>/<a class="drug drug_general" data-topicid="10045" href="/z/d/drug information/10045.html" rel="external">vincristine</a> therapy or selumetinib. The mTOR inhibitor, <a class="drug drug_general" data-topicid="9078" href="/z/d/drug information/9078.html" rel="external">everolimus</a>, has also shown efficacy. In a multicenter phase II trial in 23 patients with recurrent/progressive NF1-associated LGGs, 15 of 22 patients demonstrated a clinical response to oral everolimus (1 complete response, 2 partial responses, 12 with stable disease) [<a href="#rid76">76</a>].</p><p>For adults, there is no specific treatment for NF1-associated LGGs. They are generally treated according to the histologic pathology; patients with pilocytic astrocytomas are often managed with surveillance, while those with diffuse LGGs may be offered treatment with radiation [<a href="#rid77">77</a>].</p><p>Contrary to previous literature, approximately one-third of patients with progressive optic pathway glioma (OPG) treated with chemotherapy may regain some lost vision [<a href="#rid78">78,79</a>]. Radiation is avoided in pediatric patients with NF1 due to the increased risk of secondary malignancy and moyamoya [<a href="#rid52">52,54,80</a>]. Alkylating agents have typically been avoided as well due to concern for secondary malignancy; however, a retrospective analysis did not find a significantly increased risk of secondary neoplasm associated with the use of alkylating agents in patients with NF1 [<a href="#rid54">54</a>].</p><p>The surveillance for and monitoring of OPGs are discussed above, and treatment is discussed in greater detail separately. (See <a class="local">'Optic pathway gliomas'</a> above and  <a class="medical medical_review" href="/z/d/html/5226.html" rel="external">"Optic pathway glioma", section on 'Treatment'</a>.)</p><p class="headingAnchor" id="H2765022755"><span class="h3">High-grade gliomas</span><span class="headingEndMark"> — </span>When a high-grade glioma (HGG) is suspected, biopsy or surgical resection is recommended. There is tremendous variability in treatment practices for HGGs. Pediatric HGGs are treated similar to sporadic cases with maximum safe surgical resection and usually radiation therapy [<a href="#rid81">81</a>]. Adults with HGGs are usually offered conventional radiation, at times with concurrent <a class="drug drug_general" data-topicid="9699" href="/z/d/drug information/9699.html" rel="external">temozolomide</a>.</p><p>The observed age of occurrence of NF1-associated glioblastoma in adults, mean of 38.3 years, is much younger than the mean age for patients with sporadic glioblastoma. There is evidence that NF1-associated glioblastoma may comprise a unique subset of isocitrate dehydrogenase (IDH) wildtype tumors [<a href="#rid82">82</a>]. Treatment will likely continue to evolve given the advancing molecular understanding of NF1-related tumors and targeted therapies [<a href="#rid77">77</a>].</p><p class="headingAnchor" id="H196003579"><span class="h3">Malignant peripheral nerve sheath tumors</span><span class="headingEndMark"> — </span>MPNSTs are staged and treated as malignant soft tissue sarcomas [<a href="#rid83">83</a>]. Treatment includes surgical resection and adjunctive radiation therapy. A study of the utility of preoperative imaging to detect atypical neurofibromatous neoplasms of uncertain biologic potential (ANNUBP) using magnetic resonance imaging (MRI) and 18F-FDG-PET SUVmax demonstrated the feasibility of safe fascicle-sparing marginal resection with intraoperative nerve stimulation and microdissection of nerve fascicles [<a href="#rid84">84</a>]. This approach can theoretically prevent progression to MPNST. The use of chemotherapy for high-grade, unresectable MPNST is also under investigation. A preclinical study showed dramatic tumor shrinkage in a transgenic MPNST mouse model in response to combined HSP90 and mTOR inhibition [<a href="#rid85">85</a>]. Despite the promising preclinical rationale and tolerability, a phase I/II study of ganetespib, a novel injectable inhibitor of HSP90 and the mTOR inhibitor, <a class="drug drug_general" data-topicid="10329" href="/z/d/drug information/10329.html" rel="external">sirolimus</a> failed to show a response (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fclassic.clinicaltrials.gov%2Fct2%2Fshow%2FNCT02008877&amp;token=Ste%2FJ%2B0Zk8%2BGCpKsBOssVXs7REdxnziGg6IyMw%2BTV0KDbRivO5wpXLhD8Vgeu4G03hJmjf3KaUVBqz7HCLMW0A%3D%3D&amp;TOPIC_ID=90123" target="_blank">NCT02008877</a>) [<a href="#rid86">86,87</a>]. Another novel approach undergoing phase I study uses the oncolytic potential of the genetically engineered injectable measles virus Edmonston vaccine strain (MVEdm) that encodes thyroid sodium iodide symporter [<a href="#rid88">88</a>]. (See  <a class="medical medical_review" href="/z/d/html/15269.html" rel="external">"Peripheral nerve tumors", section on 'Treatment of MPNSTs'</a> and  <a class="medical medical_review" href="/z/d/html/15269.html" rel="external">"Peripheral nerve tumors", section on 'Prognosis'</a> and  <a class="medical medical_review" href="/z/d/html/7732.html" rel="external">"Treatment of locally recurrent and unresectable, locally advanced soft tissue sarcoma of the extremities"</a> and  <a class="medical medical_review" href="/z/d/html/7743.html" rel="external">"Overview of the initial treatment of metastatic soft tissue sarcoma"</a>.)</p><p class="headingAnchor" id="H196003585"><span class="h3">Rhabdomyosarcoma</span><span class="headingEndMark"> — </span>Treatment of rhabdomyosarcoma includes chemotherapy, surgery if feasible, and radiation therapy. These are discussed in greater detail separately. (See  <a class="medical medical_review" href="/z/d/html/7721.html" rel="external">"Rhabdomyosarcoma in childhood, adolescence, and adulthood: Treatment"</a>.)</p><p class="headingAnchor" id="H196003591"><span class="h3">Gastrointestinal stromal tumors</span><span class="headingEndMark"> — </span>Most gastrointestinal stromal tumors (GISTs) in patients with NF1 do not carry somatic mutations in the v-Kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homologue (<em>KIT</em>) or platelet-derived growth factor receptor alpha (<em>PDGFRA</em>) genes, unlike GISTs that arise outside of the setting of NF1 [<a href="#rid89">89,90</a>]. Consistent with this finding, these tumors in patients with NF1 are poorly responsive to the tyrosine kinase inhibitor <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">imatinib</a> [<a href="#rid90">90,91</a>]. (See  <a class="medical medical_review" href="/z/d/html/7725.html" rel="external">"Tyrosine kinase inhibitor therapy for advanced gastrointestinal stromal tumors"</a> and <a class="local">'Pheochromocytoma in patients with GIST'</a> above.)</p><p class="headingAnchor" id="H196003597"><span class="h2">Neurologic abnormalities</span><span class="headingEndMark"> — </span>Neurologic disorders that may require specific management include cognitive deficits, learning disabilities, seizures, and peripheral neuropathy. Adults with NF1 are also at risk for headaches, including migraines, and sleep disorders, which are managed the same as in the general population.</p><p class="headingAnchor" id="H196003603"><span class="h3">Cognitive and learning deficits</span><span class="headingEndMark"> — </span>Children with learning disabilities should receive academic support. Speech, occupational, and physical therapy should be provided for children with speech problems and motor impairment involving balance and gait. Some children have attention-deficit disorder, with or without hyperactivity, which may respond to stimulant medication [<a href="#rid92">92,93</a>]. (See  <a class="medical medical_review" href="/z/d/html/623.html" rel="external">"Attention deficit hyperactivity disorder in children and adolescents: Overview of treatment and prognosis"</a> and  <a class="medical medical_review" href="/z/d/html/16927.html" rel="external">"Attention deficit hyperactivity disorder in children and adolescents: Treatment with medications", section on 'Stimulants versus other medications'</a> and  <a class="medical medical_review" href="/z/d/html/624.html" rel="external">"Attention deficit hyperactivity disorder in children and adolescents: Clinical features and diagnosis", section on 'Core symptoms'</a> and  <a class="medical medical_review" href="/z/d/html/624.html" rel="external">"Attention deficit hyperactivity disorder in children and adolescents: Clinical features and diagnosis", section on 'Clinical features'</a>.)</p><p>Statin drugs were hypothesized to be a potential treatment for cognitive and learning deficits in NF1 based on preclinical mouse model data [<a href="#rid94">94</a>], but two randomized trials in children with NF1 failed to confirm a benefit [<a href="#rid95">95-97</a>].</p><p class="headingAnchor" id="H196003609"><span class="h3">Seizures</span><span class="headingEndMark"> — </span>The management of seizures in patients with NF1 is similar to that of seizures due to other causes and is discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/6203.html" rel="external">"Seizures and epilepsy in children: Initial treatment and monitoring"</a> and  <a class="medical medical_review" href="/z/d/html/2220.html" rel="external">"Overview of the management of epilepsy in adults"</a>.)</p><p class="headingAnchor" id="H196003615"><span class="h3">Peripheral neuropathy</span><span class="headingEndMark"> — </span>Management of peripheral neuropathies involves treatment of the underlying disease process, if possible (eg, nerve compression due to a tumor), and alleviation of symptoms. A generalized polyneuropathy may occur in some adults in the absence of a compressive lesion [<a href="#rid98">98-100</a>]. (See  <a class="medical medical_review" href="/z/d/html/5284.html" rel="external">"Overview of polyneuropathy"</a> and  <a class="medical medical_review" href="/z/d/html/6254.html" rel="external">"Pain in children: Approach to pain assessment and overview of management principles"</a> and  <a class="medical medical_review" href="/z/d/html/126111.html" rel="external">"Approach to the management of chronic non-cancer pain in adults", section on 'General approach'</a>.)</p><p class="headingAnchor" id="H196003621"><span class="h2">Bone abnormalities</span><span class="headingEndMark"> — </span>Orthopedic intervention may be needed for tibial or other long-bone dysplasia and scoliosis. Other bone abnormalities, such as osteoporosis, may not respond as well to typical therapies, although further studies are needed. Vitamin D supplementation is advised for all persons with NF1 and vitamin D deficiency or insufficiency. Treatment of osteoporosis with calcium and vitamin D alone did not appear to increase bone density in a small trial [<a href="#rid101">101</a>]. Studies are needed to determine whether early intervention with bisphosphonates is indicated. (See  <a class="medical medical_review" href="/z/d/html/14590.html" rel="external">"Vitamin D insufficiency and deficiency in children and adolescents"</a> and  <a class="medical medical_review" href="/z/d/html/2022.html" rel="external">"Vitamin D deficiency in adults: Definition, clinical manifestations, and treatment"</a>.)</p><p class="headingAnchor" id="H196003627"><span class="h3">Pseudoarthrosis</span><span class="headingEndMark"> — </span>Mobility may be improved by amputation of the lower leg and replacement with a prosthesis in some patients with tibial pseudoarthrosis [<a href="#rid102">102</a>]. A number of other surgical and pharmacologic approaches to managing tibial pseudoarthrosis are under investigation [<a href="#rid103">103</a>]. If possible, these patients should be evaluated by an orthopedics team that has experience with NF1, given the complexity of these lesions.</p><p class="headingAnchor" id="H196003633"><span class="h3">Short stature</span><span class="headingEndMark"> — </span>Growth hormone therapy for short stature may be used to bring growth hormone to physiologic levels. Although concern has been raised that growth hormone could lead to tumor growth, there are no studies demonstrating that this has occurred. (See  <a class="medical medical_review" href="/z/d/html/5824.html" rel="external">"Growth hormone treatment for idiopathic short stature"</a>.)</p><p class="headingAnchor" id="H196003639"><span class="h3">Scoliosis</span><span class="headingEndMark"> — </span>Screening for spine deformity by physical examination should begin at diagnosis and be repeated yearly. To limit radiation exposure in the pediatric population, consensus-based guidelines recommend diagnostic spine imaging only if clinical suspicion arises from patient history or physical examination [<a href="#rid104">104</a>]. Orthopedic intervention, such as bracing or surgery, may be needed for scoliosis [<a href="#rid105">105,106</a>]. Spinal tumor burden must be assessed preoperatively in any patient with NF1 undergoing surgery for scoliosis. Magnetically controlled growing rods (MCGR) impede visualization of spinal tumors by MRI, especially intraspinal tumors, and MCGRs are not recommended when spinal tumor burden is high [<a href="#rid104">104</a>]. (See  <a class="medical medical_review" href="/z/d/html/6291.html" rel="external">"Adolescent idiopathic scoliosis: Management and prognosis", section on 'Treatment modalities'</a>.)</p><p>The requirement for surgical management of dystrophic scoliosis may further complicate the clinical picture of chronic pain management for persons with NF1 [<a href="#rid107">107</a>]. (See  <a class="medical medical_review" href="/z/d/html/6254.html" rel="external">"Pain in children: Approach to pain assessment and overview of management principles"</a> and  <a class="medical medical_review" href="/z/d/html/126111.html" rel="external">"Approach to the management of chronic non-cancer pain in adults"</a>.)</p><p class="headingAnchor" id="H196003651"><span class="h2">Psychosocial issues</span><span class="headingEndMark"> — </span>Specific counseling may be warranted for patients, particularly adolescents, with NF1 who face issues with self-esteem and the psychosocial impact of this condition [<a href="#rid108">108,109</a>].</p><p class="headingAnchor" id="H196003657"><span class="h2">Hypertension</span><span class="headingEndMark"> — </span>The general management of primary hypertension and hypertension associated with renovascular disease or pheochromocytoma is discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/6131.html" rel="external">"Nonemergent treatment of hypertension in children and adolescents"</a> and  <a class="medical medical_review" href="/z/d/html/3869.html" rel="external">"Choice of drug therapy in primary (essential) hypertension"</a> and  <a class="medical medical_review" href="/z/d/html/3834.html" rel="external">"Treatment of unilateral atherosclerotic renal artery stenosis"</a> and  <a class="medical medical_review" href="/z/d/html/3836.html" rel="external">"Treatment of bilateral atherosclerotic renal artery stenosis or stenosis to a solitary functioning kidney"</a> and  <a class="medical medical_review" href="/z/d/html/142.html" rel="external">"Treatment of pheochromocytoma in adults"</a> and  <a class="medical medical_review" href="/z/d/html/6468.html" rel="external">"Initial management of hypertensive emergencies and urgencies in children", section on 'Hypertensive emergency'</a>.)</p><p class="headingAnchor" id="H689416237"><span class="h2">Pulmonary complications</span><span class="headingEndMark"> — </span>Pulmonary complications include neurofibromas, cysts, emphysematous changes, and fibrosis [<a href="#rid110">110-112</a>]. Although these are rare, they can cause significant morbidity and even mortality. Treatment for these complications is the same as for pathologically similar pulmonary problems in the general population.</p><p class="headingAnchor" id="H196003663"><span class="h1">GENETIC COUNSELING</span><span class="headingEndMark"> — </span>NF1 has an autosomal-dominant inheritance pattern. Counseling should be provided for patients and families. It should include information on the inheritance of the disorder (including potential recurrence risk in other offspring), prognosis, and psychosocial adjustment. The progressive nature of the disease and the variability in clinical presentation should be addressed. (See  <a class="medical medical_review" href="/z/d/html/2901.html" rel="external">"Genetic testing"</a>.)</p><p>Reproductive decisions by couples are facilitated by appropriate genetic counseling about the availability of prenatal or preimplantation testing (see  <a class="medical medical_review" href="/z/d/html/2939.html" rel="external">"Neurofibromatosis type 1 (NF1): Pathogenesis, clinical features, and diagnosis", section on 'Prenatal testing'</a> and  <a class="medical medical_review" href="/z/d/html/103304.html" rel="external">"Genetic counseling: Family history interpretation and risk assessment"</a>). Prospective parents should be aware that NF1 exhibits wide clinical variability within families and that establishing the diagnosis prenatally cannot predict the severity or outcome. The couple should also be informed that their risk of having an affected child can be substantially lowered by use of other reproductive technologies, including sperm or oocyte donation, depending upon which parent is affected. (See  <a class="medical medical_review" href="/z/d/html/7404.html" rel="external">"In vitro fertilization: Overview of clinical issues and questions", section on 'When are donor oocytes used?'</a> and  <a class="medical medical_review" href="/z/d/html/7423.html" rel="external">"Donor insemination"</a>.)</p><p>The risk of having this disorder in each offspring of an affected parent is 50 percent. If a couple has one child with NF1 and neither parent meets the clinical criteria for NF1 (see  <a class="medical medical_review" href="/z/d/html/2939.html" rel="external">"Neurofibromatosis type 1 (NF1): Pathogenesis, clinical features, and diagnosis", section on 'Diagnostic criteria'</a>), the risk of the parents having another child with NF1 is less than 1 percent. When this occurs, it is most often caused by germline mosaicism such that a proportion of the gonadal tissue contains the mutation [<a href="#rid113">113,114</a>]. The rate of germline mosaicism in NF1 is much lower than in NF2, osteogenesis imperfecta, and some other dominant disorders [<a href="#rid115">115</a>].</p><p>The risk of having a child with generalized NF1 is substantially reduced for patients with segmental disease (0 to 50 percent) compared with generalized disease (50 percent), but it is not possible to quantify a precise risk. Animal studies suggest that the risk is proportional to the percentage of body area involved [<a href="#rid116">116</a>]. If a person with segmental NF1 has an affected offspring, that child will carry the mutation in all cells of the body and will have generalized NF1, not segmental disease.</p><p>The <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.ctf.org%2F&amp;token=F2fTJXWTbAdqtiUVhUGfEX%2ByQ%2FSsqWqNANGkzTP5RAQ%3D&amp;TOPIC_ID=90123" target="_blank">Children's Tumor Foundation</a> provides information about the disorder and general support. Referral of the family to a local chapter often is helpful.</p><p class="headingAnchor" id="H196003669"><span class="h1">PROGNOSIS</span><span class="headingEndMark"> — </span>Survival data in persons with NF1 are limited, although several studies have highlighted the decreased life expectancy in persons with NF1, particularly women, compared with the general population [<a href="#rid117">117-119</a>].</p><p>In one report using data from United States death certificates from 1983 through 1997, the age at death was reduced for NF1 patients compared with that of the general population (median 59 versus 74 years, respectively) [<a href="#rid117">117</a>]. NF1 patients were more likely to have a malignant neoplasm listed on their death certificates, especially if death occurred before they reached 30 years of age. Similarly, in large cohort studies, the disease-specific survival of patients with NF1 who develop cancer is lower than that of comparable patients with sporadic cancers [<a href="#rid119">119,120</a>].</p><p class="headingAnchor" id="H196003675"><span class="h2">Prognosis of CNS tumors</span><span class="headingEndMark"> — </span>The natural history of central nervous system (CNS) tumors in persons with NF1 is not well documented.</p><p>In a retrospective French study, treatment was undertaken in the minority of patients with both optic pathway glioma (OPG) and extraoptic pathway tumors [<a href="#rid121">121</a>]. Despite this, the 5- and 10-year survival rates were 90 and 82 percent when all patients were considered. Factors associated with significantly shorter survival were extraoptic location and tumor diagnosis in adulthood. Growth hormone deficiency (46 percent) and ischemic stroke (32 percent) were frequent complications of radiotherapy in patients with OPG.</p><p>Patients with NF1 and CNS tumors are at increased risk for early mortality, second CNS malignancies, and vascular complications [<a href="#rid52">52,122</a>]. In one report of 154 NF1 patients with OPG, 11 percent had a second CNS tumor [<a href="#rid123">123</a>]. The risk of non-CNS tumors was not increased by the presence of an optic pathway tumor.</p><p>OPGs appear to have a more benign course in patients with NF1 than in those without NF1, but there may be a degree of ascertainment bias since patients with NF1 are screened for OPGs, whereas sporadic cases are only identified when they are symptomatic or a brain scan is undertaken for other reasons. (See  <a class="medical medical_review" href="/z/d/html/5226.html" rel="external">"Optic pathway glioma"</a>.)</p><p>The behavior and prognosis of extraoptic gliomas in adults with NF1 are variable [<a href="#rid121">121</a>]. NF1-associated low-grade gliomas (LGGs) in adults may behave more aggressively than their histology may predict [<a href="#rid124">124</a>]. Conversely, there is some evidence indicating that adults with NF1 and high-grade gliomas (HGGs) may have better outcomes than HGGs in the general population [<a href="#rid125">125</a>]. Studies evaluating alternative lengthening of telomeres (ALT) and loss of ATRX, an X-linked helicase, indicate that these alterations are predictive of aggressive behavior in NF1-associated gliomas. Specifically, ALT is present in 60 percent of histologically defined HGGs, but only 19 percent of histologically defined LGGs. ALT was independently associated with worse survival accounting for grade and age [<a href="#rid77">77,126</a>].</p><p class="headingAnchor" id="H196003681"><span class="h2">Prognosis of MPNST</span><span class="headingEndMark"> — </span>Malignant peripheral nerve sheath tumor (MPNST) is an aggressive and potentially fatal malignancy. Outcomes are generally poor for patients that are not able to have complete resection. Historically, survival rates in patients with NF1 were lower than in patients with sporadic MPNST [<a href="#rid31">31,127</a>]. This difference has all but disappeared, with significantly improved survival rates seen in patients with NF1 since the early 2000s [<a href="#rid83">83,128,129</a>]. Three-year disease-specific survival was 64 percent in one series, and five-year overall survival was approximately 40 to 55 percent in two other series. (See  <a class="medical medical_review" href="/z/d/html/15269.html" rel="external">"Peripheral nerve tumors", section on 'Prognosis'</a>.)</p><p class="headingAnchor" id="H196003687"><span class="h2">Prognosis of rhabdomyosarcoma</span><span class="headingEndMark"> — </span>Treatment outcomes for rhabdomyosarcoma in patients with NF1 appear similar to those in the general population with rhabdomyosarcoma [<a href="#rid127">127</a>]. (See  <a class="medical medical_review" href="/z/d/html/7721.html" rel="external">"Rhabdomyosarcoma in childhood, adolescence, and adulthood: Treatment"</a>.)</p><p class="headingAnchor" id="H2966450501"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/117263.html" rel="external">"Society guideline links: Neurofibromatosis type 1"</a>.)</p><p class="headingAnchor" id="H196003693"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topic (see  <a class="medical medical_basics" href="/z/d/html/87115.html" rel="external">"Patient education: Neurofibromatosis type 1 (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H196003699"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Longitudinal care</strong> – Longitudinal care for persons with neurofibromatosis type 1 (NF1) aims at the early detection and symptomatic treatment of complications as they occur. In providing <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fpublications.aap.org%2Fpediatrics%2Farticle%2F121%2F3%2F633%2F72846%2FHealth-Supervision-for-Children-With&amp;token=WDQdv7yj%2BX3tPjR%2B5EfDlU9r8F7JW%2BPpnh5xXt5PwfKlRXNfw3Cs7%2B2DxPOMo0UndLiBeCDSh3mnwGYBQ15%2BW02gAASCbYGah%2BzJF2ttS%2F8SQq7ozgHDSLTSHgE7Bpry2CTmDFEkE0W677HPEp26Ew%3D%3D&amp;TOPIC_ID=90123" target="_blank">medical supervision</a> to children with NF1, the frequency of follow-up visits should increase to address disease complications as they arise. (See <a class="local">'Annual surveillance for all children with NF1'</a> above and <a class="local">'Surveillance for adults with NF1'</a> above.)</p><p></p><p class="bulletIndent1">The decision to obtain diagnostic studies depends upon the history and physical findings. Clinical evaluation appears to be more useful to detect complications than are screening investigations in asymptomatic patients. (See <a class="local">'Surveillance for specific complications or presentations'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment of complications</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Tumors</strong> – The approach to treatment of the various tumors associated with NF1 depends upon the type of tumor, its effect on adjacent tissues, and related complications. Surgical treatment and pain management of plexiform neurofibromas (PNs) can be challenging. Surgical resection often is limited to debulking of a specific area of a large lesion. Progressive or symptomatic plexiform neurofibromas may be treated with mitogen-activated protein kinase kinase (MEK) inhibitors. (See <a class="local">'Tumors'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Neurologic disorders</strong> – Neurologic disorders that may require specific management include cognitive deficits, learning disabilities, seizures, and peripheral neuropathy. (See <a class="local">'Neurologic abnormalities'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Bone abnormalities</strong> – Orthopedic intervention may be needed for long bone dysplasia and scoliosis. Other bone abnormalities, such as osteoporosis, may not respond as well to typical therapies. (See <a class="local">'Bone abnormalities'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Counseling</strong> – Counseling should be provided for affected persons and families. It should include information on the inheritance of the disorder, prognosis, and psychosocial adjustment. The progressive nature of the disease and its clinical manifestations and complications should be addressed. (See <a class="local">'Psychosocial issues'</a> above and <a class="local">'Genetic counseling'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prognosis</strong> – Information about the effect of NF1 on mortality is limited, although life expectancy appears to be shortened. Malignant neoplasms, particularly malignant peripheral nerve sheath tumors (MPNST), are the primary cause of decreased survival. (See <a class="local">'Prognosis'</a> above.)</p><p></p><p><strong>ACKNOWLEDGMENT</strong> — The UpToDate editorial staff acknowledges Sharon E Plon, MD, PhD, who contributed to an earlier version of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Miller DT, Freedenberg D, Schorry E, et al. Health Supervision for Children With Neurofibromatosis Type 1. Pediatrics 2019; 143.</a></li><li><a class="nounderline abstract_t">Gutmann DH, Aylsworth A, Carey JC, et al. The diagnostic evaluation and multidisciplinary management of neurofibromatosis 1 and neurofibromatosis 2. JAMA 1997; 278:51.</a></li><li><a class="nounderline abstract_t">Wolkenstein P, Frèche B, Zeller J, Revuz J. Usefulness of screening investigations in neurofibromatosis type 1. A study of 152 patients. Arch Dermatol 1996; 132:1333.</a></li><li><a class="nounderline abstract_t">Lama G, Graziano L, Calabrese E, et al. Blood pressure and cardiovascular involvement in children with neurofibromatosis type1. Pediatr Nephrol 2004; 19:413.</a></li><li><a class="nounderline abstract_t">Stewart DR, Korf BR, Nathanson KL, et al. Care of adults with neurofibromatosis type 1: a clinical practice resource of the American College of Medical Genetics and Genomics (ACMG). Genet Med 2018; 20:671.</a></li><li><a class="nounderline abstract_t">Miettinen MM, Antonescu CR, Fletcher CDM, et al. Histopathologic evaluation of atypical neurofibromatous tumors and their transformation into malignant peripheral nerve sheath tumor in patients with neurofibromatosis 1-a consensus overview. Hum Pathol 2017; 67:1.</a></li><li><a class="nounderline abstract_t">Ferner RE, Gutmann DH. International consensus statement on malignant peripheral nerve sheath tumors in neurofibromatosis. Cancer Res 2002; 62:1573.</a></li><li><a class="nounderline abstract_t">Ferner RE, Golding JF, Smith M, et al. [18F]2-fluoro-2-deoxy-D-glucose positron emission tomography (FDG PET) as a diagnostic tool for neurofibromatosis 1 (NF1) associated malignant peripheral nerve sheath tumours (MPNSTs): a long-term clinical study. Ann Oncol 2008; 19:390.</a></li><li><a class="nounderline abstract_t">Warbey VS, Ferner RE, Dunn JT, et al. [18F]FDG PET/CT in the diagnosis of malignant peripheral nerve sheath tumours in neurofibromatosis type-1. Eur J Nucl Med Mol Imaging 2009; 36:751.</a></li><li><a class="nounderline abstract_t">Benz MR, Czernin J, Dry SM, et al. Quantitative F18-fluorodeoxyglucose positron emission tomography accurately characterizes peripheral nerve sheath tumors as malignant or benign. Cancer 2010; 116:451.</a></li><li><a class="nounderline abstract_t">Evans DGR, Kallionpää RA, Clementi M, et al. Breast cancer in neurofibromatosis 1: survival and risk of contralateral breast cancer in a five country cohort study. Genet Med 2020; 22:398.</a></li><li><a class="nounderline abstract_t">Képénékian L, Mognetti T, Lifante JC, et al. Interest of systematic screening of pheochromocytoma in patients with neurofibromatosis type 1. Eur J Endocrinol 2016; 175:335.</a></li><li><a class="nounderline abstract_t">Petr EJ, Else T. Pheochromocytoma and Paraganglioma in Neurofibromatosis type 1: frequent surgeries and cardiovascular crises indicate the need for screening. Clin Diabetes Endocrinol 2018; 4:15.</a></li><li><a class="nounderline abstract_t">Rea D, Brandsema JF, Armstrong D, et al. Cerebral arteriopathy in children with neurofibromatosis type 1. Pediatrics 2009; 124:e476.</a></li><li><a class="nounderline abstract_t">Szudek J, Birch P, Friedman JM. Growth in North American white children with neurofibromatosis 1 (NF1). J Med Genet 2000; 37:933.</a></li><li><a class="nounderline abstract_t">Clementi M, Milani S, Mammi I, et al. Neurofibromatosis type 1 growth charts. Am J Med Genet 1999; 87:317.</a></li><li><a class="nounderline abstract_t">Listernick R, Ferner RE, Liu GT, Gutmann DH. Optic pathway gliomas in neurofibromatosis-1: controversies and recommendations. Ann Neurol 2007; 61:189.</a></li><li><a class="nounderline abstract_t">Hersh JH, American Academy of Pediatrics Committee on Genetics. Health supervision for children with neurofibromatosis. Pediatrics 2008; 121:633.</a></li><li><a class="nounderline abstract_t">Cambiaso P, Galassi S, Palmiero M, et al. Growth hormone excess in children with neurofibromatosis type-1 and optic glioma. Am J Med Genet A 2017; 173:2353.</a></li><li><a class="nounderline abstract_t">Bizzarri C, Bottaro G. Endocrine implications of neurofibromatosis 1 in childhood. Horm Res Paediatr 2015; 83:232.</a></li><li><a class="nounderline abstract_t">Listernick R, Charrow J. Knowledge without truth: screening for complications of neurofibromatosis type 1 in childhood. Am J Med Genet A 2004; 127A:221.</a></li><li><a class="nounderline abstract_t">Prada CE, Hufnagel RB, Hummel TR, et al. The Use of Magnetic Resonance Imaging Screening for Optic Pathway Gliomas in Children with Neurofibromatosis Type 1. J Pediatr 2015; 167:851.</a></li><li><a class="nounderline abstract_t">Blazo MA, Lewis RA, Chintagumpala MM, et al. Outcomes of systematic screening for optic pathway tumors in children with Neurofibromatosis Type 1. Am J Med Genet A 2004; 127A:224.</a></li><li><a class="nounderline abstract_t">Thiagalingam S, Flaherty M, Billson F, North K. Neurofibromatosis type 1 and optic pathway gliomas: follow-up of 54 patients. Ophthalmology 2004; 111:568.</a></li><li><a class="nounderline abstract_t">Listernick R, Louis DN, Packer RJ, Gutmann DH. Optic pathway gliomas in children with neurofibromatosis 1: consensus statement from the NF1 Optic Pathway Glioma Task Force. Ann Neurol 1997; 41:143.</a></li><li><a class="nounderline abstract_t">Balcer LJ, Liu GT, Heller G, et al. Visual loss in children with neurofibromatosis type 1 and optic pathway gliomas: relation to tumor location by magnetic resonance imaging. Am J Ophthalmol 2001; 131:442.</a></li><li><a class="nounderline abstract_t">Liu GT. Optic gliomas of the anterior visual pathway. Curr Opin Ophthalmol 2006; 17:427.</a></li><li><a class="nounderline abstract_t">Avery RA, Liu GT, Fisher MJ, et al. Retinal nerve fiber layer thickness in children with optic pathway gliomas. Am J Ophthalmol 2011; 151:542.</a></li><li><a class="nounderline abstract_t">Serdaroglu E, Konuskan B, Karli Oguz K, et al. Epilepsy in neurofibromatosis type 1: Diffuse cerebral dysfunction? Epilepsy Behav 2019; 98:6.</a></li><li><a class="nounderline abstract_t">Nix JS, Blakeley J, Rodriguez FJ. An update on the central nervous system manifestations of neurofibromatosis type 1. Acta Neuropathol 2020; 139:625.</a></li><li><a class="nounderline abstract_t">Porter DE, Prasad V, Foster L, et al. Survival in Malignant Peripheral Nerve Sheath Tumours: A Comparison between Sporadic and Neurofibromatosis Type 1-Associated Tumours. Sarcoma 2009; 2009:756395.</a></li><li><a class="nounderline abstract_t">Matsumine A, Kusuzaki K, Nakamura T, et al. Differentiation between neurofibromas and malignant peripheral nerve sheath tumors in neurofibromatosis 1 evaluated by MRI. J Cancer Res Clin Oncol 2009; 135:891.</a></li><li><a class="nounderline abstract_t">Koike H, Nishida Y, Ito S, et al. Diffusion-Weighted Magnetic Resonance Imaging Improves the Accuracy of Differentiation of Benign from Malignant Peripheral Nerve Sheath Tumors. World Neurosurg 2022; 157:e207.</a></li><li><a class="nounderline abstract_t">De Raedt T, Brems H, Wolkenstein P, et al. Elevated risk for MPNST in NF1 microdeletion patients. Am J Hum Genet 2003; 72:1288.</a></li><li><a class="nounderline abstract_t">Evans DGR, Salvador H, Chang VY, et al. Cancer and Central Nervous System Tumor Surveillance in Pediatric Neurofibromatosis 1. Clin Cancer Res 2017; 23:e46.</a></li><li><a class="nounderline abstract_t">Raad RA, Lala S, Allen JC, et al. Comparison of hybrid 18F-fluorodeoxyglucose positron emission tomography/magnetic resonance imaging and positron emission tomography/computed tomography for evaluation of peripheral nerve sheath tumors in patients with neurofibromatosis type 1. World J Nucl Med 2018; 17:241.</a></li><li><a class="nounderline abstract_t">Higham CS, Dombi E, Rogiers A, et al. The characteristics of 76 atypical neurofibromas as precursors to neurofibromatosis 1 associated malignant peripheral nerve sheath tumors. Neuro Oncol 2018; 20:818.</a></li><li><a class="nounderline abstract_t">Meany H, Dombi E, Reynolds J, et al. 18-fluorodeoxyglucose-positron emission tomography (FDG-PET) evaluation of nodular lesions in patients with Neurofibromatosis type 1 and plexiform neurofibromas (PN) or malignant peripheral nerve sheath tumors (MPNST). Pediatr Blood Cancer 2013; 60:59.</a></li><li><a class="nounderline abstract_t">Vlenterie M, Flucke U, Hofbauer LC, et al. Pheochromocytoma and gastrointestinal stromal tumors in patients with neurofibromatosis type I. Am J Med 2013; 126:174.</a></li><li><a class="nounderline abstract_t">Ejerskov C, Krogh K, Ostergaard JR, et al. Gastrointestinal Symptoms in Children and Adolescents With Neurofibromatosis Type 1. J Pediatr Gastroenterol Nutr 2018; 66:872.</a></li><li><a class="nounderline abstract_t">Ejerskov C, Krogh K, Ostergaard JR, et al. Constipation in adults with neurofibromatosis type 1. Orphanet J Rare Dis 2017; 12:139.</a></li><li><a class="nounderline abstract_t">Cornett KM, North KN, Rose KJ, Burns J. Muscle weakness in children with neurofibromatosis type 1. Dev Med Child Neurol 2015; 57:733.</a></li><li><a class="nounderline abstract_t">Chinoy A, Vassallo GR, Burkitt Wright E, et al. The skeletal muscle phenotype of children with Neurofibromatosis Type 1 - A clinical perspective. J Musculoskelet Neuronal Interact 2022; 22:70.</a></li><li><a class="nounderline abstract_t">Summers MA, Rupasinghe T, Vasiljevski ER, et al. Dietary intervention rescues myopathy associated with neurofibromatosis type 1. Hum Mol Genet 2018; 27:577.</a></li><li><a class="nounderline abstract_t">Vasiljevski ER, Burns J, Bray P, et al. L-carnitine supplementation for muscle weakness and fatigue in children with neurofibromatosis type 1: A Phase 2a clinical trial. Am J Med Genet A 2021; 185:2976.</a></li><li><a class="nounderline abstract_t">Fossali E, Signorini E, Intermite RC, et al. Renovascular disease and hypertension in children with neurofibromatosis. Pediatr Nephrol 2000; 14:806.</a></li><li><a class="nounderline abstract_t">Walsh KS, Vélez JI, Kardel PG, et al. Symptomatology of autism spectrum disorder in a population with neurofibromatosis type 1. Dev Med Child Neurol 2013; 55:131.</a></li><li><a class="nounderline abstract_t">North KN, Riccardi V, Samango-Sprouse C, et al. Cognitive function and academic performance in neurofibromatosis. 1: consensus statement from the NF1 Cognitive Disorders Task Force. Neurology 1997; 48:1121.</a></li><li><a class="nounderline abstract_t">Chetty SP, Shaffer BL, Norton ME. Management of pregnancy in women with genetic disorders: Part 2: Inborn errors of metabolism, cystic fibrosis, neurofibromatosis type 1, and Turner syndrome in pregnancy. Obstet Gynecol Surv 2011; 66:765.</a></li><li><a class="nounderline abstract_t">Terry AR, Barker FG 2nd, Leffert L, et al. Neurofibromatosis type 1 and pregnancy complications: a population-based study. Am J Obstet Gynecol 2013; 209:46.e1.</a></li><li><a class="nounderline abstract_t">Gutmann DH, Blakeley JO, Korf BR, Packer RJ. Optimizing biologically targeted clinical trials for neurofibromatosis. Expert Opin Investig Drugs 2013; 22:443.</a></li><li><a class="nounderline abstract_t">Sharif S, Ferner R, Birch JM, et al. Second primary tumors in neurofibromatosis 1 patients treated for optic glioma: substantial risks after radiotherapy. J Clin Oncol 2006; 24:2570.</a></li><li><a class="nounderline abstract_t">de Blank P, Li N, Ullrich NJ, et al. Neurofibromatosis type 1 and risk of late outcomes after a primary tumor: A report from the Childhood Cancer Survivor Study [Abstract]. J Clin Oncol 2018; 36(Suppl):10563.</a></li><li><a class="nounderline abstract_t">Bhatia S, Chen Y, Wong FL, et al. Subsequent Neoplasms After a Primary Tumor in Individuals With Neurofibromatosis Type 1. J Clin Oncol 2019; 37:3050.</a></li><li><a class="nounderline abstract_t">Ortonne N, Wolkenstein P, Blakeley JO, et al. Cutaneous neurofibromas: Current clinical and pathologic issues. Neurology 2018; 91:S5.</a></li><li><a class="nounderline abstract_t">Jensen SE, Patel ZS, Listernick R, et al. Lifespan Development: Symptoms Experienced by Individuals with Neurofibromatosis Type 1 Associated Plexiform Neurofibromas from Childhood into Adulthood. J Clin Psychol Med Settings 2019; 26:259.</a></li><li><a class="nounderline abstract_t">Gross AM, Singh G, Akshintala S, et al. Association of plexiform neurofibroma volume changes and development of clinical morbidities in neurofibromatosis 1. Neuro Oncol 2018; 20:1643.</a></li><li><a class="nounderline abstract_t">Dunn GP, Spiliopoulos K, Plotkin SR, et al. Role of resection of malignant peripheral nerve sheath tumors in patients with neurofibromatosis type 1. J Neurosurg 2013; 118:142.</a></li><li><a class="nounderline abstract_t">Gutmann DH. Recent insights into neurofibromatosis type 1: clear genetic progress. Arch Neurol 1998; 55:778.</a></li><li><a class="nounderline abstract_t">Canavese F, Krajbich JI. Resection of plexiform neurofibromas in children with neurofibromatosis type 1. J Pediatr Orthop 2011; 31:303.</a></li><li class="breakAll">https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213756s000lbl.pdf.</li><li><a class="nounderline abstract_t">Gross AM, Wolters PL, Dombi E, et al. Selumetinib in Children with Inoperable Plexiform Neurofibromas. N Engl J Med 2020; 382:1430.</a></li><li><a class="nounderline abstract_t">Gross AM, Dombi E, Wolters PL, et al. Long-term safety and efficacy of selumetinib in children with neurofibromatosis type 1 on a phase 1/2 trial for inoperable plexiform neurofibromas. Neuro Oncol 2023; 25:1883.</a></li><li><a class="nounderline abstract_t">Hwang J, Yoon HM, Lee BH, et al. Efficacy and Safety of Selumetinib in Pediatric Patients With Neurofibromatosis Type 1: A Systematic Review and Meta-analysis. Neurology 2022; 98:e938.</a></li><li><a class="nounderline abstract_t">Weiss BD, Wolters PL, Plotkin SR, et al. NF106: A Neurofibromatosis Clinical Trials Consortium Phase II Trial of the MEK Inhibitor Mirdametinib (PD-0325901) in Adolescents and Adults With NF1-Related Plexiform Neurofibromas. J Clin Oncol 2021; 39:797.</a></li><li><a class="nounderline abstract_t">Fisher MJ, Shih CS, Rhodes SD, et al. Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial. Nat Med 2021; 27:165.</a></li><li><a class="nounderline abstract_t">Robertson KA, Nalepa G, Yang FC, et al. Imatinib mesylate for plexiform neurofibromas in patients with neurofibromatosis type 1: a phase 2 trial. Lancet Oncol 2012; 13:1218.</a></li><li><a class="nounderline abstract_t">Jakacki RI, Dombi E, Potter DM, et al. Phase I trial of pegylated interferon-alpha-2b in young patients with plexiform neurofibromas. Neurology 2011; 76:265.</a></li><li><a class="nounderline abstract_t">Jakacki RI, Dombi E, Steinberg SM, et al. Phase II trial of pegylated interferon alfa-2b in young patients with neurofibromatosis type 1 and unresectable plexiform neurofibromas. Neuro Oncol 2017; 19:289.</a></li><li><a class="nounderline abstract_t">Widemann BC, Salzer WL, Arceci RJ, et al. Phase I trial and pharmacokinetic study of the farnesyltransferase inhibitor tipifarnib in children with refractory solid tumors or neurofibromatosis type I and plexiform neurofibromas. J Clin Oncol 2006; 24:507.</a></li><li><a class="nounderline abstract_t">Weiss B, Widemann BC, Wolters P, et al. Sirolimus for non-progressive NF1-associated plexiform neurofibromas: an NF clinical trials consortium phase II study. Pediatr Blood Cancer 2014; 61:982.</a></li><li><a class="nounderline abstract_t">Weiss B, Widemann BC, Wolters P, et al. Sirolimus for progressive neurofibromatosis type 1-associated plexiform neurofibromas: a neurofibromatosis Clinical Trials Consortium phase II study. Neuro Oncol 2015; 17:596.</a></li><li><a class="nounderline abstract_t">Widemann BC, Babovic-Vuksanovic D, Dombi E, et al. Phase II trial of pirfenidone in children and young adults with neurofibromatosis type 1 and progressive plexiform neurofibromas. Pediatr Blood Cancer 2014; 61:1598.</a></li><li><a class="nounderline abstract_t">Lassaletta A, Scheinemann K, Zelcer SM, et al. Phase II Weekly Vinblastine for Chemotherapy-Naïve Children With Progressive Low-Grade Glioma: A Canadian Pediatric Brain Tumor Consortium Study. J Clin Oncol 2016.</a></li><li><a class="nounderline abstract_t">Fangusaro J, Onar-Thomas A, Young Poussaint T, et al. Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial. Lancet Oncol 2019; 20:1011.</a></li><li><a class="nounderline abstract_t">Ullrich NJ, Prabhu SP, Reddy AT, et al. A phase II study of continuous oral mTOR inhibitor everolimus for recurrent, radiographic-progressive neurofibromatosis type 1-associated pediatric low-grade glioma: a Neurofibromatosis Clinical Trials Consortium study. Neuro Oncol 2020; 22:1527.</a></li><li><a class="nounderline abstract_t">Packer RJ, Iavarone A, Jones DTW, et al. Implications of new understandings of gliomas in children and adults with NF1: report of a consensus conference. Neuro Oncol 2020; 22:773.</a></li><li><a class="nounderline abstract_t">Fisher MJ, Loguidice M, Gutmann DH, et al. Visual outcomes in children with neurofibromatosis type 1-associated optic pathway glioma following chemotherapy: a multicenter retrospective analysis. Neuro Oncol 2012; 14:790.</a></li><li><a class="nounderline abstract_t">Falzon K, Drimtzias E, Picton S, Simmons I. Visual outcomes after chemotherapy for optic pathway glioma in children with and without neurofibromatosis type 1: results of the International Society of Paediatric Oncology (SIOP) Low-Grade Glioma 2004 trial UK cohort. Br J Ophthalmol 2018; 102:1367.</a></li><li><a class="nounderline abstract_t">Sievert AJ, Fisher MJ. Pediatric low-grade gliomas. J Child Neurol 2009; 24:1397.</a></li><li><a class="nounderline abstract_t">Michaeli O, Tabori U. Pediatric High Grade Gliomas in the Context of Cancer Predisposition Syndromes. J Korean Neurosurg Soc 2018; 61:319.</a></li><li><a class="nounderline abstract_t">Lobbous M, Bernstock JD, Coffee E, et al. An Update on Neurofibromatosis Type 1-Associated Gliomas. Cancers (Basel) 2020; 12:114.</a></li><li><a class="nounderline abstract_t">LaFemina J, Qin LX, Moraco NH, et al. Oncologic outcomes of sporadic, neurofibromatosis-associated, and radiation-induced malignant peripheral nerve sheath tumors. Ann Surg Oncol 2013; 20:66.</a></li><li><a class="nounderline abstract_t">Nelson CN, Dombi E, Rosenblum JS, et al. Safe marginal resection of atypical neurofibromas in neurofibromatosis type 1. J Neurosurg 2019; :1.</a></li><li><a class="nounderline abstract_t">De Raedt T, Walton Z, Yecies JL, et al. Exploiting cancer cell vulnerabilities to develop a combination therapy for ras-driven tumors. Cancer Cell 2011; 20:400.</a></li><li><a class="nounderline abstract_t">Kim A, Lu Y, Okuno SH, et al. Targeting Refractory Sarcomas and Malignant Peripheral Nerve Sheath Tumors in a Phase I/II Study of Sirolimus in Combination with Ganetespib (SARC023). Sarcoma 2020; 2020:5784876.</a></li><li><a class="nounderline abstract_t">Kim A, Reinke DK, Cichowski K, et al.. SARC023: Phase I/II trial of ganetespib in combination with sirolimus for refractory sarcomas and malignant peripheral nerve sheath tumors (MPNST) [Abstract]. J Clin Oncol 2017; 32(Suppl 15):10603.</a></li><li><a class="nounderline abstract_t">Deyle DR, Escobar DZ, Peng KW, Babovic-Vuksanovic D. Oncolytic measles virus as a novel therapy for malignant peripheral nerve sheath tumors. Gene 2015; 565:140.</a></li><li><a class="nounderline abstract_t">Miettinen M, Fetsch JF, Sobin LH, Lasota J. Gastrointestinal stromal tumors in patients with neurofibromatosis 1: a clinicopathologic and molecular genetic study of 45 cases. Am J Surg Pathol 2006; 30:90.</a></li><li><a class="nounderline abstract_t">Mussi C, Schildhaus HU, Gronchi A, et al. Therapeutic consequences from molecular biology for gastrointestinal stromal tumor patients affected by neurofibromatosis type 1. Clin Cancer Res 2008; 14:4550.</a></li><li><a class="nounderline abstract_t">Izquierdo ME, Bonastre MT. Patient with high-risk GIST not associated with c-KIT mutations: same benefit from adjuvant therapy? Anticancer Drugs 2012; 23 Suppl:S7.</a></li><li><a class="nounderline abstract_t">Cohen R, Halevy A, Aharon S, Shuper A. Attention Deficit Hyperactivity Disorder in Neurofibromatosis Type 1: Evaluation with a Continuous Performance Test. J Clin Neurol 2018; 14:153.</a></li><li><a class="nounderline abstract_t">Pride NA, Barton B, Hutchins P, et al. Effects of methylphenidate on cognition and behaviour in children with neurofibromatosis type 1: a study protocol for a randomised placebo-controlled crossover trial. BMJ Open 2018; 8:e021800.</a></li><li><a class="nounderline abstract_t">Li W, Cui Y, Kushner SA, et al. The HMG-CoA reductase inhibitor lovastatin reverses the learning and attention deficits in a mouse model of neurofibromatosis type 1. Curr Biol 2005; 15:1961.</a></li><li><a class="nounderline abstract_t">Krab LC, de Goede-Bolder A, Aarsen FK, et al. Effect of simvastatin on cognitive functioning in children with neurofibromatosis type 1: a randomized controlled trial. JAMA 2008; 300:287.</a></li><li><a class="nounderline abstract_t">van der Vaart T, Plasschaert E, Rietman AB, et al. Simvastatin for cognitive deficits and behavioural problems in patients with neurofibromatosis type 1 (NF1-SIMCODA): a randomised, placebo-controlled trial. Lancet Neurol 2013; 12:1076.</a></li><li><a class="nounderline abstract_t">Payne JM, Barton B, Ullrich NJ, et al. Randomized placebo-controlled study of lovastatin in children with neurofibromatosis type 1. Neurology 2016; 87:2575.</a></li><li><a class="nounderline abstract_t">Schulz A, Grafe P, Hagel C, et al. Neuropathies in the setting of Neurofibromatosis tumor syndromes: Complexities and opportunities. Exp Neurol 2018; 299:334.</a></li><li><a class="nounderline abstract_t">Pegat A, Ducray F, Jeannin-Mayer S, et al. Charcot-Marie-Tooth (CMT)-like polyneuropathy revealing neurofibromatosis type 2: A case report and review of the literature. Rev Neurol (Paris) 2019; 175:486.</a></li><li><a class="nounderline abstract_t">Terracciano C, Pachatz C, Rastelli E, et al. Neurofibromatous neuropathy: An ultrastructural study. Ultrastruct Pathol 2018; 42:312.</a></li><li><a class="nounderline abstract_t">Brunetti-Pierri N, Doty SB, Hicks J, et al. Generalized metabolic bone disease in Neurofibromatosis type I. Mol Genet Metab 2008; 94:105.</a></li><li><a class="nounderline abstract_t">Stevenson DA, Birch PH, Friedman JM, et al. Descriptive analysis of tibial pseudarthrosis in patients with neurofibromatosis 1. Am J Med Genet 1999; 84:413.</a></li><li><a class="nounderline abstract_t">Stevenson DA, Little D, Armstrong L, et al. Approaches to treating NF1 tibial pseudarthrosis: consensus from the Children's Tumor Foundation NF1 Bone Abnormalities Consortium. J Pediatr Orthop 2013; 33:269.</a></li><li><a class="nounderline abstract_t">Xu AL, Suresh KV, Gomez JA, et al. Consensus-Based Best Practice Guidelines for the Management of Spinal Deformity and Associated Tumors in Pediatric Neurofibromatosis Type 1: Screening and Surveillance, Surgical Intervention, and Medical Therapy. J Pediatr Orthop 2023; 43:e531.</a></li><li><a class="nounderline abstract_t">Suresh KV, Xu AL, Groves ML, Sponseller PD. Spinal screening, malignancy, medical therapy, and surgical correction of deformity in pediatric patients with neurofibromatosis type 1: a systematic review. J Pediatr Orthop B 2022; 31:572.</a></li><li><a class="nounderline abstract_t">Mladenov KV, Spiro AS, Krajewski KL, et al. Management of spinal deformities and tibial pseudarthrosis in children with neurofibromatosis type 1 (NF-1). Childs Nerv Syst 2020; 36:2409.</a></li><li><a class="nounderline abstract_t">Crawford AH, Herrera-Soto J. Scoliosis associated with neurofibromatosis. Orthop Clin North Am 2007; 38:553.</a></li><li><a class="nounderline abstract_t">Bogadi M, Kastelan S, Bakija I, Kasun B. Psychiatric disorders in patients with neurofibromatosis. Libri Oncol 2018; 46:105.</a></li><li><a class="nounderline abstract_t">Lemogne C, Bellivier F, Fakra E, et al. Psychological and psychiatric aspects of face transplantation: Lessons learned from the long-term follow-up of six patients. J Psychosom Res 2019; 119:42.</a></li><li><a class="nounderline abstract_t">Reviron-Rabec L, Girerd B, Seferian A, et al. Pulmonary complications of type 1 neurofibromatosis. Rev Mal Respir 2016; 33:460.</a></li><li><a class="nounderline abstract_t">Alves Júnior SF, Zanetti G, Alves de Melo AS, et al. Neurofibromatosis type 1: State-of-the-art review with emphasis on pulmonary involvement. Respir Med 2019; 149:9.</a></li><li><a class="nounderline abstract_t">Spinnato P, Facchini G, Tetta C, et al. Neurofibromatosis type-1-associated diffuse lung disease in children. Pediatr Pulmonol 2019; 54:1760.</a></li><li><a class="nounderline abstract_t">Lázaro C, Ravella A, Gaona A, et al. Neurofibromatosis type 1 due to germ-line mosaicism in a clinically normal father. N Engl J Med 1994; 331:1403.</a></li><li><a class="nounderline abstract_t">Riccardi VM, Lewis RA. Penetrance of von Recklinghausen neurofibromatosis: a distinction between predecessors and descendants. Am J Hum Genet 1988; 42:284.</a></li><li><a class="nounderline abstract_t">Zlotogora J. Germ line mosaicism. Hum Genet 1998; 102:381.</a></li><li><a class="nounderline abstract_t">Ruggieri M, Huson SM. The clinical and diagnostic implications of mosaicism in the neurofibromatoses. Neurology 2001; 56:1433.</a></li><li><a class="nounderline abstract_t">Rasmussen SA, Yang Q, Friedman JM. Mortality in neurofibromatosis 1: an analysis using U.S. death certificates. Am J Hum Genet 2001; 68:1110.</a></li><li><a class="nounderline abstract_t">Uusitalo E, Leppävirta J, Koffert A, et al. Incidence and mortality of neurofibromatosis: a total population study in Finland. J Invest Dermatol 2015; 135:904.</a></li><li><a class="nounderline abstract_t">Uusitalo E, Rantanen M, Kallionpää RA, et al. Distinctive Cancer Associations in Patients With Neurofibromatosis Type 1. J Clin Oncol 2016; 34:1978.</a></li><li><a class="nounderline abstract_t">Landry JP, Schertz KL, Chiang YJ, et al. Comparison of Cancer Prevalence in Patients With Neurofibromatosis Type 1 at an Academic Cancer Center vs in the General Population From 1985 to 2020. JAMA Netw Open 2021; 4:e210945.</a></li><li><a class="nounderline abstract_t">Guillamo JS, Créange A, Kalifa C, et al. Prognostic factors of CNS tumours in Neurofibromatosis 1 (NF1): a retrospective study of 104 patients. Brain 2003; 126:152.</a></li><li><a class="nounderline abstract_t">de Blank P, Li N, Fisher MJ, et al. Late morbidity and mortality in adult survivors of childhood glioma with neurofibromatosis type 1: report from the Childhood Cancer Survivor Study. Genet Med 2020; 22:1794.</a></li><li><a class="nounderline abstract_t">Friedman JM, Birch P. An association between optic glioma and other tumours of the central nervous system in neurofibromatosis type 1. Neuropediatrics 1997; 28:131.</a></li><li><a class="nounderline abstract_t">Strowd RE 3rd, Rodriguez FJ, McLendon RE, et al. Histologically benign, clinically aggressive: Progressive non-optic pathway pilocytic astrocytomas in adults with NF1. Am J Med Genet A 2016; 170:1455.</a></li><li><a class="nounderline abstract_t">Theeler BJ, Ellezam B, Yust-Katz S, et al. Prolonged survival in adult neurofibromatosis type I patients with recurrent high-grade gliomas treated with bevacizumab. J Neurol 2014; 261:1559.</a></li><li><a class="nounderline abstract_t">Rodriguez FJ, Graham MK, Brosnan-Cashman JA, et al. Telomere alterations in neurofibromatosis type 1-associated solid tumors. Acta Neuropathol Commun 2019; 7:139.</a></li><li><a class="nounderline abstract_t">Ferrari A, Bisogno G, Macaluso A, et al. Soft-tissue sarcomas in children and adolescents with neurofibromatosis type 1. Cancer 2007; 109:1406.</a></li><li><a class="nounderline abstract_t">Ingham S, Huson SM, Moran A, et al. Malignant peripheral nerve sheath tumours in NF1: improved survival in women and in recent years. Eur J Cancer 2011; 47:2723.</a></li><li><a class="nounderline abstract_t">Kolberg M, Høland M, Agesen TH, et al. Survival meta-analyses for &gt;1800 malignant peripheral nerve sheath tumor patients with and without neurofibromatosis type 1. Neuro Oncol 2013; 15:135.</a></li></ol></div><div id="topicVersionRevision">Topic 90123 Version 26.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31010905" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Health Supervision for Children With Neurofibromatosis Type 1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9207339" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : The diagnostic evaluation and multidisciplinary management of neurofibromatosis 1 and neurofibromatosis 2.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8915311" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Usefulness of screening investigations in neurofibromatosis type 1. A study of 152 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14991390" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Blood pressure and cardiovascular involvement in children with neurofibromatosis type1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30006586" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Care of adults with neurofibromatosis type 1: a clinical practice resource of the American College of Medical Genetics and Genomics (ACMG).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28551330" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Histopathologic evaluation of atypical neurofibromatous tumors and their transformation into malignant peripheral nerve sheath tumor in patients with neurofibromatosis 1-a consensus overview.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11894862" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : International consensus statement on malignant peripheral nerve sheath tumors in neurofibromatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17932395" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : [18F]2-fluoro-2-deoxy-D-glucose positron emission tomography (FDG PET) as a diagnostic tool for neurofibromatosis 1 (NF1) associated malignant peripheral nerve sheath tumours (MPNSTs): a long-term clinical study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19142634" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : [18F]FDG PET/CT in the diagnosis of malignant peripheral nerve sheath tumours in neurofibromatosis type-1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19924789" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Quantitative F18-fluorodeoxyglucose positron emission tomography accurately characterizes peripheral nerve sheath tumors as malignant or benign.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31495828" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Breast cancer in neurofibromatosis 1: survival and risk of contralateral breast cancer in a five country cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27450695" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Interest of systematic screening of pheochromocytoma in patients with neurofibromatosis type 1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29977594" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Pheochromocytoma and Paraganglioma in Neurofibromatosis type 1: frequent surgeries and cardiovascular crises indicate the need for screening.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19706560" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Cerebral arteriopathy in children with neurofibromatosis type 1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11106357" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Growth in North American white children with neurofibromatosis 1 (NF1).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10588837" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Neurofibromatosis type 1 growth charts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17387725" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Optic pathway gliomas in neurofibromatosis-1: controversies and recommendations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18310216" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Health supervision for children with neurofibromatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28631895" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Growth hormone excess in children with neurofibromatosis type-1 and optic glioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25659607" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Endocrine implications of neurofibromatosis 1 in childhood.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15150769" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Knowledge without truth: screening for complications of neurofibromatosis type 1 in childhood.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26233602" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : The Use of Magnetic Resonance Imaging Screening for Optic Pathway Gliomas in Children with Neurofibromatosis Type 1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15150770" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Outcomes of systematic screening for optic pathway tumors in children with Neurofibromatosis Type 1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15019338" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Neurofibromatosis type 1 and optic pathway gliomas: follow-up of 54 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9029062" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Optic pathway gliomas in children with neurofibromatosis 1: consensus statement from the NF1 Optic Pathway Glioma Task Force.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11292406" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Visual loss in children with neurofibromatosis type 1 and optic pathway gliomas: relation to tumor location by magnetic resonance imaging.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16932058" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Optic gliomas of the anterior visual pathway.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21232732" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Retinal nerve fiber layer thickness in children with optic pathway gliomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31299535" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Epilepsy in neurofibromatosis type 1: Diffuse cerebral dysfunction?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30963251" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : An update on the central nervous system manifestations of neurofibromatosis type 1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19360115" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Survival in Malignant Peripheral Nerve Sheath Tumours: A Comparison between Sporadic and Neurofibromatosis Type 1-Associated Tumours.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19101731" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Differentiation between neurofibromas and malignant peripheral nerve sheath tumors in neurofibromatosis 1 evaluated by MRI.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34624521" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Diffusion-Weighted Magnetic Resonance Imaging Improves the Accuracy of Differentiation of Benign from Malignant Peripheral Nerve Sheath Tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12660952" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Elevated risk for MPNST in NF1 microdeletion patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28620004" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Cancer and Central Nervous System Tumor Surveillance in Pediatric Neurofibromatosis 1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30505221" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Comparison of hybrid 18F-fluorodeoxyglucose positron emission tomography/magnetic resonance imaging and positron emission tomography/computed tomography for evaluation of peripheral nerve sheath tumors in patients with neurofibromatosis type 1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29409029" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : The characteristics of 76 atypical neurofibromas as precursors to neurofibromatosis 1 associated malignant peripheral nerve sheath tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22645095" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : 18-fluorodeoxyglucose-positron emission tomography (FDG-PET) evaluation of nodular lesions in patients with Neurofibromatosis type 1 and plexiform neurofibromas (PN) or malignant peripheral nerve sheath tumors (MPNST).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23331445" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Pheochromocytoma and gastrointestinal stromal tumors in patients with neurofibromatosis type I.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29240009" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Gastrointestinal Symptoms in Children and Adolescents With Neurofibromatosis Type 1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28814319" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Constipation in adults with neurofibromatosis type 1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25913846" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Muscle weakness in children with neurofibromatosis type 1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35234161" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : The skeletal muscle phenotype of children with Neurofibromatosis Type 1 - A clinical perspective.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29228356" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Dietary intervention rescues myopathy associated with neurofibromatosis type 1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34155781" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : L-carnitine supplementation for muscle weakness and fatigue in children with neurofibromatosis type 1: A Phase 2a clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10955932" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Renovascular disease and hypertension in children with neurofibromatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23163951" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Symptomatology of autism spectrum disorder in a population with neurofibromatosis type 1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9109916" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Cognitive function and academic performance in neurofibromatosis. 1: consensus statement from the NF1 Cognitive Disorders Task Force.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22192461" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Management of pregnancy in women with genetic disorders: Part 2: Inborn errors of metabolism, cystic fibrosis, neurofibromatosis type 1, and Turner syndrome in pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23535241" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Neurofibromatosis type 1 and pregnancy complications: a population-based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23425047" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Optimizing biologically targeted clinical trials for neurofibromatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16735710" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Second primary tumors in neurofibromatosis 1 patients treated for optic glioma: substantial risks after radiotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Neurofibromatosis type 1 and risk of late outcomes after a primary tumor: A report from the Childhood Cancer Survivor Study [Abstract]</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31532722" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Subsequent Neoplasms After a Primary Tumor in Individuals With Neurofibromatosis Type 1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29987130" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Cutaneous neurofibromas: Current clinical and pathologic issues.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30298332" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Lifespan Development: Symptoms Experienced by Individuals with Neurofibromatosis Type 1 Associated Plexiform Neurofibromas from Childhood into Adulthood.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29718344" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Association of plexiform neurofibroma volume changes and development of clinical morbidities in neurofibromatosis 1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23101443" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Role of resection of malignant peripheral nerve sheath tumors in patients with neurofibromatosis type 1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9626767" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Recent insights into neurofibromatosis type 1: clear genetic progress.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21415691" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Resection of plexiform neurofibromas in children with neurofibromatosis type 1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21415691" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Resection of plexiform neurofibromas in children with neurofibromatosis type 1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32187457" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Selumetinib in Children with Inoperable Plexiform Neurofibromas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37115514" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Long-term safety and efficacy of selumetinib in children with neurofibromatosis type 1 on a phase 1/2 trial for inoperable plexiform neurofibromas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35017312" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Efficacy and Safety of Selumetinib in Pediatric Patients With Neurofibromatosis Type 1: A Systematic Review and Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33507822" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : NF106: A Neurofibromatosis Clinical Trials Consortium Phase II Trial of the MEK Inhibitor Mirdametinib (PD-0325901) in Adolescents and Adults With NF1-Related Plexiform Neurofibromas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33442015" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23099009" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Imatinib mesylate for plexiform neurofibromas in patients with neurofibromatosis type 1: a phase 2 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21242495" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Phase I trial of pegylated interferon-alpha-2b in young patients with plexiform neurofibromas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27510726" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Phase II trial of pegylated interferon alfa-2b in young patients with neurofibromatosis type 1 and unresectable plexiform neurofibromas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16421428" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Phase I trial and pharmacokinetic study of the farnesyltransferase inhibitor tipifarnib in children with refractory solid tumors or neurofibromatosis type I and plexiform neurofibromas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24851266" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Sirolimus for non-progressive NF1-associated plexiform neurofibromas: an NF clinical trials consortium phase II study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25314964" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Sirolimus for progressive neurofibromatosis type 1-associated plexiform neurofibromas: a neurofibromatosis Clinical Trials Consortium phase II study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24753394" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Phase II trial of pirfenidone in children and young adults with neurofibromatosis type 1 and progressive plexiform neurofibromas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27573663" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Phase II Weekly Vinblastine for Chemotherapy-Naïve Children With Progressive Low-Grade Glioma: A Canadian Pediatric Brain Tumor Consortium Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31151904" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32236425" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : A phase II study of continuous oral mTOR inhibitor everolimus for recurrent, radiographic-progressive neurofibromatosis type 1-associated pediatric low-grade glioma: a Neurofibromatosis Clinical Trials Consortium study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32055852" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Implications of new understandings of gliomas in children and adults with NF1: report of a consensus conference.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22474213" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Visual outcomes in children with neurofibromatosis type 1-associated optic pathway glioma following chemotherapy: a multicenter retrospective analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29343527" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Visual outcomes after chemotherapy for optic pathway glioma in children with and without neurofibromatosis type 1: results of the International Society of Paediatric Oncology (SIOP) Low-Grade Glioma 2004 trial UK cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19841428" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Pediatric low-grade gliomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29742882" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Pediatric High Grade Gliomas in the Context of Cancer Predisposition Syndromes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31906320" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : An Update on Neurofibromatosis Type 1-Associated Gliomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22878618" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Oncologic outcomes of sporadic, neurofibromatosis-associated, and radiation-induced malignant peripheral nerve sheath tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31653805" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Safe marginal resection of atypical neurofibromas in neurofibromatosis type 1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21907929" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Exploiting cancer cell vulnerabilities to develop a combination therapy for ras-driven tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32089640" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Targeting Refractory Sarcomas and Malignant Peripheral Nerve Sheath Tumors in a Phase I/II Study of Sirolimus in Combination with Ganetespib (SARC023).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : SARC023: Phase I/II trial of ganetespib in combination with sirolimus for refractory sarcomas and malignant peripheral nerve sheath tumors (MPNST) [Abstract]</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25843626" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Oncolytic measles virus as a novel therapy for malignant peripheral nerve sheath tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16330947" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Gastrointestinal stromal tumors in patients with neurofibromatosis 1: a clinicopathologic and molecular genetic study of 45 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18628470" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Therapeutic consequences from molecular biology for gastrointestinal stromal tumor patients affected by neurofibromatosis type 1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22739668" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Patient with high-risk GIST not associated with c-KIT mutations: same benefit from adjuvant therapy?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29629523" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Attention Deficit Hyperactivity Disorder in Neurofibromatosis Type 1: Evaluation with a Continuous Performance Test.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30166301" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Effects of methylphenidate on cognition and behaviour in children with neurofibromatosis type 1: a study protocol for a randomised placebo-controlled crossover trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16271875" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : The HMG-CoA reductase inhibitor lovastatin reverses the learning and attention deficits in a mouse model of neurofibromatosis type 1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18632543" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Effect of simvastatin on cognitive functioning in children with neurofibromatosis type 1: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24090588" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Simvastatin for cognitive deficits and behavioural problems in patients with neurofibromatosis type 1 (NF1-SIMCODA): a randomised, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27956565" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Randomized placebo-controlled study of lovastatin in children with neurofibromatosis type 1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28587874" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Neuropathies in the setting of Neurofibromatosis tumor syndromes: Complexities and opportunities.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31221421" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Charcot-Marie-Tooth (CMT)-like polyneuropathy revealing neurofibromatosis type 2: A case report and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29583067" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Neurofibromatous neuropathy: An ultrastructural study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18289904" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Generalized metabolic bone disease in Neurofibromatosis type I.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10360395" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Descriptive analysis of tibial pseudarthrosis in patients with neurofibromatosis 1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23482262" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Approaches to treating NF1 tibial pseudarthrosis: consensus from the Children's Tumor Foundation NF1 Bone Abnormalities Consortium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37253707" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Consensus-Based Best Practice Guidelines for the Management of Spinal Deformity and Associated Tumors in Pediatric Neurofibromatosis Type 1: Screening and Surveillance, Surgical Intervention, and Medical Therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35132000" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Spinal screening, malignancy, medical therapy, and surgical correction of deformity in pediatric patients with neurofibromatosis type 1: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32613421" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Management of spinal deformities and tibial pseudarthrosis in children with neurofibromatosis type 1 (NF-1).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17945135" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Scoliosis associated with neurofibromatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Psychiatric disorders in patients with neurofibromatosis</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30947816" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Psychological and psychiatric aspects of face transplantation: Lessons learned from the long-term follow-up of six patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26868668" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Pulmonary complications of type 1 neurofibromatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30885426" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Neurofibromatosis type 1: State-of-the-art review with emphasis on pulmonary involvement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31411009" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Neurofibromatosis type-1-associated diffuse lung disease in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7969279" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Neurofibromatosis type 1 due to germ-line mosaicism in a clinically normal father.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3124613" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Penetrance of von Recklinghausen neurofibromatosis: a distinction between predecessors and descendants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9600231" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Germ line mosaicism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11409413" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : The clinical and diagnostic implications of mosaicism in the neurofibromatoses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11283797" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Mortality in neurofibromatosis 1: an analysis using U.S. death certificates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25354145" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Incidence and mortality of neurofibromatosis: a total population study in Finland.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26926675" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : Distinctive Cancer Associations in Patients With Neurofibromatosis Type 1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33734413" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : Comparison of Cancer Prevalence in Patients With Neurofibromatosis Type 1 at an Academic Cancer Center vs in the General Population From 1985 to 2020.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12477702" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : Prognostic factors of CNS tumours in Neurofibromatosis 1 (NF1): a retrospective study of 104 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32572180" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : Late morbidity and mortality in adult survivors of childhood glioma with neurofibromatosis type 1: report from the Childhood Cancer Survivor Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9208416" id="rid122" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>123 : An association between optic glioma and other tumours of the central nervous system in neurofibromatosis type 1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26992069" id="rid123" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>124 : Histologically benign, clinically aggressive: Progressive non-optic pathway pilocytic astrocytomas in adults with NF1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24859329" id="rid124" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>125 : Prolonged survival in adult neurofibromatosis type I patients with recurrent high-grade gliomas treated with bevacizumab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31462295" id="rid125" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>126 : Telomere alterations in neurofibromatosis type 1-associated solid tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17330850" id="rid126" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>127 : Soft-tissue sarcomas in children and adolescents with neurofibromatosis type 1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21700447" id="rid127" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>128 : Malignant peripheral nerve sheath tumours in NF1: improved survival in women and in recent years.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23161774" id="rid128" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>129 : Survival meta-analyses for&gt;1800 malignant peripheral nerve sheath tumor patients with and without neurofibromatosis type 1.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
